close

Fenwick Represents Audentes in $75.4 Million Follow-On Offering

April 28, 2017

Fenwick & West represented Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, in its $75.4 million follow-on offering of common stock. Audentes sold 5,200,000 shares of common stock at a price to the public of $14.50 per share. As part of the offering, Audentes granted the underwriters a 30-day option to purchase up to an additional 780,000 shares of common stock.

BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as joint book-running managers for the offering. Wedbush PacGrow acted as a co-manager.

The Fenwick transaction team included corporate partners Robert Freedman and Effie Toshav, and corporate associates Amanda Rose, Liz Federowicz, and Shiva Mirzanian.